Background: Cutaneous pustular disorders include generalized pustular psoriasis (GPP) and acute generalized exanthematous pustulosis (AGEP). Objective: To identify differences between GPP and AGEP, here we immunohistochemically evaluated interleukin (IL)-36 and the IL-23/Th17 axis. Methods: This retrospective comparative immunohistochemical study was completed using 11 biopsies of 11 cases of GPP and 11 biopsies of 11 cases of AGEP. Through staining with the anti-IL-36-alpha (IL-36α), anti-IL-36 receptor antagonist (IL-36Ra), anti-nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), anti-IL-23, anti-IL-17, and anti-IL-8 antibodies, main expression location and intensity were visualized in the epidermis and dermis. Results: In both diseases, diffuse IL-36α expression was observed in the epidermis. IL-36Ra expression was observed in the dermal perivascular area as well as in the epidermis. NF-κB expression was observed in the epidermis and perivascular dermal area. Diffuse IL-23 and IL-17 expression was seen in the whole epidermis and the perivascular dermal area. IL-8 was expressed in the subcorneal pustules and parakeratotic area. Contrary to other cytokines, IL-23 expression in the epidermis of patients with GPP was more intense than only that in patients with AGEP. Conclusion: Common pathomechanisms might exist in the development of GPP and AGEP based on these immunohistochemical results, but further studies are needed. (Ann Dermatol 28(4) 451∼456, 2016) 
INTRODUCTION
Generalized pustular psoriasis (GPP) is a rare variant of psoriasis that can be fatal; therefore, systemic treatment and supportive care should be required 1, 2 . Acute generalized exanthematous pustulosis (AGEP) is a cutaneous reaction to medications, infection, and even foods 3, 4 . GPP and AGEP share common clinicopathological features characterized by widespread pustules with or without systemic symptoms such as fever, malaise, and leukocytosis 1, 5, 6 . Due to clinical similarities such as extensive pustules and systemic symptoms in two diseases, differentiation between the two diseases is quite difficult for physicians in the clinical setting. Despite several histological and immunohistochemical trials to identify differences between the two pustular disorders, no decisive differential features have been demonstrated 6, 7 .
Although the pathophysiology of each disorder remains elusive and complicated, several cytokines such as interleukin (IL)-8, IL-17, IL-23, and IL-36, which are related to both disorders, have recently been investigated [8] [9] [10] [11] [12] [13] . However, comparative immunohistochemical studies between GPP and AGEP are relatively few 7 . Mutations of the gene for IL-36 receptor antagonist (IL-36Ra) were recently reported 
Clinical parameters
Several parameters were reviewed including sex ratio, mean age, disease duration, antecedent events before pustular eruptions, previous history of psoriasis vulgaris, treatment modalities against pustular attacks, and recurrence using data from the medical records and clinical photographs.
Immunohistochemical analysis
Using formalin-fixed, paraffin-embedded specimens, hematoxylin and eosin and immunohistochemical staining were performed using antibodies against IL-36α(R&D Systems, Minneapolis, MN, USA), IL-36Ra (R&D Systems), nuclear factor kappa-light-chain-enhancer of activated B cells p65 (NF-κB; Abcam, Cambridge, UK), IL-23 (Biolegend, San Diego, CA, USA), IL-17 (Abcam), and IL-8 (Abcam). The immunohistochemical results were analyzed individually in the epidermis and dermis using Image Pro Plus Version 4.5 (Media Cybernetics Co., Silver Spring, MD, USA). The expressions of each immunohistochemical staining were determined by ratio of the stained area to measured epidermal area and dermal area on the representative area of each specimen as a blinded state. Dermal area was defined as the area within 200 μm from epidermo-dermal junction and representative area was defined as the area represents average stained area in consideration of overall tendency at each specimen. To determine the expression of NF-κB positivity, the ratio of NF-κB-positive cell count to the overall cell count within the epidermis or dermis was determined. For the NF-κB staining, positive findings were defined as strong nuclear staining, easily observed at the scanning magnification. For each frame, the tracing was repeated 3 times and the mean was determined. 
RESULTS

Clinical characteristics
Twenty-two patients visited the institution for the pustular eruptions. Based on the diagnostic definition mentioned above, 11 patients were diagnosed with GPP and 11 with AGEP. The patients' clinical characteristics are summar- 
Immunohistochemical analysis
Immunohistochemical staining using IL-36α, IL-36Ra, NF-κB, IL-23, IL-17, and IL-8 was performed. Expression location and intensity were analyzed individually in the epidermis and dermis ( Table 2 , Fig. 1 ). In GPP and AGEP, diffuse IL-36α expression was observed in the epidermal area, and their degrees of intensity were similar (0. 
DISCUSSION
The histological or clinical differentiation between GPP and AGEP is problematic, and several studies have failed to report any clear characteristics 6 . In addition, various cytokines related to each disorder were recently investigated 11, 13, 16, 20 . The principal cytokines were the IL-36 family and IL-23/Th17 axis associated cytokines. IL-36 and IL-36Ra are members of the IL-1 family and have been reported in psoriasis, especially pustular psoriasis. IL-36 is overexpressed in psoriatic lesional skin 12, 20 . On the other hand, mutations of the gene for IL-36Ra were reported in patients with intractable and severe GPP 14, 15, 17 .
Studies of IL-36 and its antagonist in patients with AGEP have also been reported 16 . In both diseases, diffuse uptake in the epidermal or perivascular dermal area was noted without significant differences. This finding suggests that the roles of IL-36α and IL-36Ra are similar in the two diseases. In addition, IL-36 activates inflammatory pathways such as the NF-κB pathway 21 . Therefore, we compared the expression of NF-κB in GPP and AGEP and observed it in the entire epidermal and perivascular dermal areas in both groups with no significant differences. The IL-23/Th17 axis is a recently well-defined psoriasis pathogenesis that has been investigated in various inflammatory disorders because it is widely involved in their pathogenesis; therefore, it is considered as a potential treatment target 10, 22, 23 . IL-23, which is produced by activated dendritic cells, stimulates T cells, which results in increased IL-17 production. The functions of IL-17 are synergized with IL-23, followed by localized skin inflammation 11 . The detection of increased IL-17-positive T lym- phocytes in AGEP was reported assisting that T helper 17 cells or IL-17 might contribute to local inflammation in both psoriasis and AGEP 13, 24 . In our study, IL-23 and IL-17 expressions were observed in the epidermis and perivascular dermal area in both diseases. IL-23 expression in the epidermis of patients with GPP was more intense than that in patients with AGEP. These findings suggest that the expression of IL-23 might play a role in the differentiation between GPP and AGEP. IL-8 is a chemokine that is secreted by various cells including epithelial cells and macrophages. Its functions include chemotaxis of neutrophils and lymphocytes and the induction of epidermal proliferations 8, 25, 26 . IL-8 is also released from T lymphocytes, which results in pustule for-mation in AGEP, while IL-8-producing cells are involved in the pathogenesis of neutrophil-rich GPP as well as AGEP 27, 28 . We consistently observed intense IL-8 expression in the epidermis, especially in the pustular and parakeratotic areas. These findings reconfirmed that IL-8 is a key molecule for neutrophilic accumulation and pustular formation in GPP and AGEP. Furthermore, these findings suggest that both disorders might share a common pathogenesis for the development of pustular eruptions. This study has some limitations. First, the biopsied specimens had different timing, i.e., each specimen has a different disease severity and course at the time of biopsy, which may influence protein expression. Furthermore, the proteins might become denatured during the paraffin-embedded procedure. From this comparative immunohistochemical study, IL-36 and the IL-23/Th17 axis in GPP and AGEP were visualized and showed similar patterns except for IL-23 expression in the epidermis. In other words, it is not definite to differentiate two diseases by immunohistochemical methods. In conclusion, our results suggest that common pathomechanisms might exist in the development of GPP and AGEP. A future well-designed study with a large number of samples is needed to differentiate between GPP and AGEP.
